Multiplex Assay Kit for Major Histocompatibility Complex Class I G (MHCG) ,etc. by FLIA (Flow Luminescence Immunoassay)

HLA-G; MHC-G; HLAG; Leukocyte Antigen G; b2 microglobulin; HLA class I histocompatibility antigen, alpha chain G

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Major Histocompatibility Complex Class I G (MHCG) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Major Histocompatibility Complex Class I G (MHCG) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Major Histocompatibility Complex Class I G (MHCG) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Major Histocompatibility Complex Class I G (MHCG) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 78-91 80
EDTA plasma(n=5) 78-91 84
heparin plasma(n=5) 87-95 91
sodium citrate plasma(n=5) 80-102 80

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Major Histocompatibility Complex Class I G (MHCG) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Major Histocompatibility Complex Class I G (MHCG) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Major Histocompatibility Complex Class I G (MHCG) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 84-104% 79-91% 87-95% 97-105%
EDTA plasma(n=5) 78-96% 87-96% 87-101% 90-101%
heparin plasma(n=5) 94-103% 86-101% 86-102% 93-104%
sodium citrate plasma(n=5) 98-105% 85-96% 85-92% 87-95%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:MHCG) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Lupus Lack of association between HLA-G 14-bp polymorphism and systemic lupus erythematosus in a Han Chinese population SAGE: source
Exp Clin Transplant Major Vascular Complications in Living-Donor Liver Transplant Recipients: Single Center Team Experience PubMed: 25894130
International Immunopharmacology Mesenchymal stem cells upregulate Treg cells via sHLA-G in SLE patients. pubmed:28129605
Scientific Reports Serum sHLA-G: Significant diagnostic biomarker with respect to therapy and immunosuppressive mediators in Head and Neck Squamous Cell Carcinoma Pubmed: 32123232
Catalog No. Related products for research use of Homo sapiens (Human) Organism species Applications (RESEARCH USE ONLY!)
RPB856Hu01 Recombinant Major Histocompatibility Complex Class I G (MHCG) Positive Control; Immunogen; SDS-PAGE; WB.
RPB856Hu02 Recombinant Major Histocompatibility Complex Class I G (MHCG) Positive Control; Immunogen; SDS-PAGE; WB.
PAB856Hu02 Polyclonal Antibody to Major Histocompatibility Complex Class I G (MHCG) WB; IHC; ICC; IP.
PAB856Hu01 Polyclonal Antibody to Major Histocompatibility Complex Class I G (MHCG) WB; IHC; ICC; IP.
LAB856Hu71 Biotin-Linked Polyclonal Antibody to Major Histocompatibility Complex Class I G (MHCG) WB; IHC; ICC.
MAB856Hu22 Monoclonal Antibody to Major Histocompatibility Complex Class I G (MHCG) WB; IHC; ICC; IP.
SEB856Hu ELISA Kit for Major Histocompatibility Complex Class I G (MHCG) Enzyme-linked immunosorbent assay for Antigen Detection.
LMB856Hu Multiplex Assay Kit for Major Histocompatibility Complex Class I G (MHCG) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.